Condition
Essential Thrombocytopenia
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Peginterferon Alfa2b
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Unknown2
Clinical Trials (2)
Showing 2 of 2 trials
NCT04226950Phase 2UnknownPrimary
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
NCT05395507Phase 2UnknownPrimary
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
Showing all 2 trials
Research Network
Common Treatments
- Peginterferon Alfa2b2
- Recombinant Interferon Alpha2
Active Sponsors
- Institute of Hematology & Blood Diseases Hospital, China2
Top Investigators
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Tianjin Medical University General Hospital